Singapore-based biomedical start-up Hummingbird Bioscience, which specializes in developing antibodies for cancer treatment, on Friday launched a new facility to expand its scientific, and research and development capabilities.
The 40,000 sq ft facility in Science Park features more than 10 state-of-the-art laboratories for biotherapeutics research with room to hire more research scientists and managers of clinical pharmacology, and the study of drugs in humans.
The biomedical sciences are now a key pillar in Singapore’s manufacturing economy, accounting for almost 3.3 percent of the local gross domestic product and employing more than 25,000 workers as of last year.
The company currently has two drugs undergoing clinical trials. The first, HMBD-001, is an antibody that targets the HER3 protein that drives tumor growth and resistance against cancer drugs. The protein is present in many solid cancers like breast, lung and colorectal cancers. The second drug undergoing clinical trials – HMBD-002 – is an antibody that enhances the ability of immune cells to fight these solid cancers.
(Source: Straits Times)